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EDITORIAL
Changing paradigms in treatment of larynx cancer
Mudando os paradigmas no tratamento do câncer de laringe
The usual concept of conservative treatment of larynx cancer 
is misinterpreted by clinicians. This concept usually refers to a 
less aggressive treatment. But the usual consideration of less 
aggressive treatment modalities are refered to radiation treat-
ment for early larynx cancer and chemoradiation for advanced 
larynx cancer. However, both treatments are not less aggressi-
ve treatments, compared to surgery, as patients are submitted 
to high doses of radiation therapy, in a daily bases, and when 
radiosensitizing chemotherapy is added to radiation therapy 
the toxicity more than doubles.1 These toxic effects related 
to mucositis, xerostomia, loss of taste, neutropenia, kidney 
impairment, hearing loss and liver toxicity are troublesome. 
For T4 patients submitted to induction chemotherapy, 56 per 
cent of them required salvage total laryngectomy.2 Of those 
with complete response and without disease, 36 per cent had a 
non-functioning larynx despite preservation of the organ.2 The 
rate of local relapse was significantly higher in the induction 
chemotherapy group.2 Disease free survival was shorter in the 
chemotherapy group, despite not being statistically significant, 
at two years.2 Looking at the sample of VA study, 75 per cent of 
patients were T1 or T2 (10%) to T3 (65%), and most were supra-
glottic cancers (62%) with only 25% of T4 lesions,2 then, not all 
cases would require total laryngectomy and could be treated 
with function sparing surgical treatment. Thus, if the sample 
were comprised with T4 lesions perhaps the results would be 
disapointing. Most of the recurrences in early larynx cancer 
after radiation therapy are more difficult to recognize in an 
early setting of recurrence, and most will require a salvage 
total laryngectomy.3 Salvage total laryngectomy after chemo-
radiation has a higher rate of complications, such as pharyngo-
cutaneous fistulas,4 and usually requires a flap for protection 
of the great vessels of neck, invariably increasing the length 
of surgery. For T1 and T2 lesions disease free survival is higher 
after surgery (100% and 79%, respectively) than radiation the-
rapy (71% and 60%, respectively) in a recent systematic review 
of Cochrane library.5 Meta-analysis of treatment options for 
T1a lesions also observed a higher rate of larynx preservation 
after transoral laser surgery than after radiation therapy.3 For 
early larynx cancer cost of transoral laser surgery is half of 
radiation therapy,6 with comparable vocal and quality of life 
outcomes to radiation therapy in a systematic review.7 The 
recent published recommendations of the American Society 
of Clinical Oncology are for function -sparing treatment for 
T1 and T2. For those T3 lesions who require total laryngec-
tomy, chemoradiation could be employed, and for T4 lesions 
the recommendation is for total laryngectomy.8 According to 
studies of tumor volumetry, the higher the tumor’s volume, 
the smaller the tumor’s response. This response relapse could 
be significant for tumor volume higher than 23 cm3.9 Those 
function -sparing surgeries range from transoral laser surgery 
to supracricoid laryngectomy, all with good quality in speech 
and swallowing. For those submitted to total laryngectomy, 
voice could be rehabilitated with insertion of voice prosthe-
sis, esophageal voice or electrolarynx. One could bear in 
mind the analysis of two American cancer registry databases, 
the SEER (Surveillance, Epidemiology, and end Results) and 
NCDB (National Cancer Data Base). As almost all cancers of 
human beings had an increase in five years disease free survi-
val for larynx cancer, this survival is decreasing, probably re-
lated to increase in non-surgical options of treatment.10 Then 
there is a need to reaffirm the surgical treatment as standard 
treatment for larynx cancer with function sparing surgeries, 
or total laryngectomy for T4 lesions, unless in the case of a 
widespread T1 or T2 lesion or T3 lesion, which requires total 
laryngectomy. 
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